Mary Caffrey

The interim update in heart failure reflects results from 10 clinical trials that have been published since the 2021 ESC Guidelines were released.

Crystal Denlinger, MD, FACP, incoming CEO of the National Comprehensive Cancer Network (NCCN), talks about the organization’s challenges and solutions to keeping up with the ever-changing oncology landscape and improving patient access to guideline-recommended treatments.

Denlinger, who spent most of her career at Fox Chase Cancer Center before joining the National Comprehensive Cancer Network (NCCN) as its chief scientific officer, took the helm October 9, 2023.

There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation.

The European Society of Cardiology (ESC) 2023 Congress runs August 25-28 in Amsterdam, the Netherlands.

Full team coverage from the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany.

Full coverage of the July 25, 2023, Institute for Value-Based Medicine session in Atlanta, Georgia, held in partnership with Winship Cancer Institute of Emory University.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

Use of SignalPath will improve efficiency, ease compliance, boost enrollment, and ensure financial success in clinical trials, leaders said in interviews.

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, explains how he works closely with patients and study sites in SURPASS-CVOT to avoid weight loss drug discontinuation and weight regain.

Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease.

Coverage from the July 25, 2023, Institute for Value-Based Medicine® session held in partnerhship with Emory's Winship Cancer Institute.

Coverage from the Institute for Value-Based Medicine event in Atlanta, held in partnership with Winship Cancer Institute of Emory University.

Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, held in partnership with Emory's Winship Cancer Institute.

Coverage of ASCO sessions and posters that addressed lessons from the Oncology Care Model and concerns about the Enhancing Oncology Model, which launched shortly after the annual meeting ended.

Results included those for several bispecifics, used as monotherapy and in combination, including early results for 2 bispecifics used together.

Presentation of the COMMANDS trial offered practice-changing results for luspatercept.

Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

An overview of the 2023 recommendations on myelodysplastic syndromes by Guillermo Garcia-Mareno, MD, of MD Anderson Cancer Center, appears in the August issue of the American Journal of Hematology.

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide.

With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, Melbourne, Australia. discusses contributions in the space from therapies with systemwide effects.

The Enhancing Oncology Model (EOM) attracted more than 2800 practitioners across 561 sites of care; a group of practices in the American Oncology Network enrolled under a single tax ID number.

A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data.

While the final number of EOM practices will be fewer than the numbers in the OCM, the presence of Tennessee Oncology, Texas Oncology, and Northwest Medical Specialties will ensure participation of key leaders who succeeded in the OCM and have weighed in on what's needed in its replacement.